Neumora Reveals Mid-Stage Data For Fully Funded, Phase III-Ready Depression Drug

Private Biotech Has Raised $650m To Date

 
• By Mandy Jackson

Neumora’s once-daily oral kappa opioid receptor (KOR) antagonist navacaprant succeeded in a Phase II trial and will move into the first of three Phase III studies soon, with a US filing targeted for 2025.

Fear, loneliness, depression, abuse, addiction
Neumora's navacaprant aims to treat anhedonia, an inability to experience pleasure or joy, in depression patients • Source: Shutterstock

More from Clinical Trials

More from R&D